ANZCTR search results

The aim of this study is to evaluate the efficacy and efficiency of two telerehabilitation interventions: 1) traditional model which is predominantly focuses on improving physical function and is currently offered as usual care by the home rehabilitation service: 2) a rehabilitation intervention which focuses more on participation in usual activities and is offered via a coaching model to a virtual group of people. Both interventions are provided in a telehealth format as a response to the global pandemic, COVID-19. The purpose is to determine whether the novel intervention is more effective as well as if it is more efficient (as it is offered in a virtual group format). We plan to recruit 58 participants who have been confirmed with COVID-19 and referred to home rehabilitation services at Flinders Medical Centre Division of Rehabilitation Aged and Palliative care. At the completion of the study, we expect to be able to describe the functional and social impacts of a telerehabilitation interventions for individuals confirmed with COVID-19 receiving home rehabilitation services.

Total Hip Arthroplasty (THA) is a procedure commonly performed in patients who have end-stage hip osteoarthritis. The primary goal of THA is to provide pain relief, reduce disability, improve quality of life and functional status. Despite high implant success rates, up to 15% of patients remain dis-satisfied after surgery. This has been postulated to be due to several factors, including implant loosening, stem fractures and reduced functional movement, which lead to poorer patient outcomes. Recently, a new range of hip replacement devices have been engineered to address some of the shortcomings of existing stems. In particular, the Quadra-P stem has specifically been designed as a straight, triple tapered stem with a rectangular cross-section and manufactured with Ti-6Al-7Nb alloy material to increase osseointegration and reduce wear. The newly designed Quadra-P stem device was recently introduced into the Australian market, however, its clinical performance is yet to be evaluated. Thus, the purpose of this study is to investigate the Quadra-P stem efficacy (survival) at 2, 5 and 10 years post-surgery and ensure that it performs just as well as other commercially available stems. The hypothesis for this investigation is that the 2, 5 and 10 year percent revision rate (need to re-implant) is not inferior (comparable) to the average performance of all other cementless femoral stems currently in use in the Australian Market.

The purpose of this study is to test the safety of a new medication (called ALMB-0168) in people with malignant bone cancer lesions either from bone cancer or from migration of other cancers. Who is it for? You may be eligible for this study if you are aged 16 or older, and have confirmed bone cancer (osteosarcoma) or cancer cells in the bone originated from other cancers which has been deemed untreatable. Study details All participants in this study will receive the active medication ALMB-0168. The dose will depend on when the participant enrolls in the study. The medication is administered through a needle in the arm, and will continue for up to 6 months. As part of this study, all participants will have additional blood tests, imaging scans and answer questions regarding to your health. It is hoped this research will demonstrate the safety of ALMB-0168 and find the ideal dose for larger-scale studies.

The purpose of this study is to trial a new program, led by nurses, for management of heart (cardiovascular) disease in people being treated for breast cancer. Who is it for? You may be eligible for this study if you are aged 18 or over and have been diagnosed with breast cancer in the last 6 months. Study details All participants in this study will receive the intervention, which is a clinical pathway lead by nurses. As part of this pathway, participant will be assessed by a nurse for their level of heart disease risk. Depending on their level of risk, they will then receive either information resources (if low risk) or a care plan including referrals to appropriate health professionals to manage their risk factors (if intermediate or high risk). The nurse will then follow up every six weeks (if possible, by telephone) to monitor how each participant is going managing/reducing their level of heart disease risk and make any adjustments to their care plan, including additional referrals, as needed. Finally, the nurse will provide each participant with a plan for ongoing management of heart disease risk at the end of participation in the study. As part of this trial, participants will complete some questionnaires, surveys and have some additional routine health tests like weighing and blood pressure. If required, the nurse may recommend for additional tests such as blood tests to be performed, so that information such as cholesterol levels can be used to calculate participant's risk of heart disease. It is hoped this research will demonstrate that this program is feasible to maintain, and acceptable to patients.

COVID-19 patients in intensive care will have their ongoing respiratory & ventilator management decided in one of two ways either 1. Using Lung Ultrasound imaging 2 The traditional method of using auscultation, arterial blood gases and ventilator settings such as static compliance Number of patients ventilated, length of stay (intensive care, hospital (time on ventilator , ventilator free days, mortality (in intensive care and at 28 day ) will be recorded and compared between the two groups. Both methods of management are standard in the intensive care units.

Metabolic imbalances at the postprandial state, particularly after a high fat meal are important contributing factors to development of cardiovascular diseases. The underlying mechanisms involves a sharp increase in triacylglycerol, a pro-inflammatory response along with an aberrant production of pro-oxidant molecules, which may impair vascular and endothelial functions. A high fat meal challenge is a method to investigate such imbalances promoted in a daily basis in Western diets. This study aims to investigate if food anthocyanins are able to attenuate these deleterious effects of high fat meals. Participants attended fasted and had a high-fat meal with either 250 ml of queen garnet plum juice (intervention rich in anthocyanins) or apricot juice (control free of anthocyanins).

This registry will include patients who present with an abnormality in the wall of their aorta (Type B aortic syndrome) with the aim of determining the natural history and clinical outcomes of this condition. Specifically, the group will look at the outcomes of patients who were treated with early intervention and/or basic medical therapy. From this study, the relationship between patient factors including kidney injury, and benefit from early intervention will be reported.

Healthcare professionals provide substandard chest compression following cardiac arrest, which is deemed a preventable harm because this skill can be acquired. The recent development of technology-enhanced cardiac compression training devices (high-fidelity mannequins) provides an alternative to traditional instructor-facilitated training. This pilot study aimes to compare the effectiveness of conventional and technology-enhanced training modalities. A pilot randomised controlled trial design will be used in a regional hospital in Queensland. Following baseline assessment, healthcare staff will be randomised to one of three groups: 1. traditional instructor-facilitated training; 2. high-fidelity mannequin training and continuous access to the training system to practise skills, and 3. high-fidelity mannequin training with no further access to the training system to practise skills. The primary outcome, cardiac compression skill levels, will be analysed using analysis of co-variance, adjusting for predictive co-variates. Secondary measures will be analysed using inferential statistics or presented descriptively.

This clinical trial is aimed to determine the effect of topically applied eye drops on focusing power of the eye and size of the eye's aperture (pupil size). This study consists of two arms. Four types of eye drops will be tested in each arm. Each different type of drops will be instilled only once and drops will be instilled only in one eye. After instillation of drops, participants will be monitored over a duration of 24 hours. During these 24 hours there will be a total of four scheduled visits. Only standard optometric procedures will be conducted during these visits. Measurements of focusing power of the eye and pupil size will be conducted using non-invasive instruments.

The purpose of this project is to investigate the feasibility and preliminary efficacy of exercise to increase prostate tumour blood flow and oxygenation as a means to improve the effectiveness of radiotherapy. Who is it for? You may be eligible to join this study if you are a male aged 18 years or over, have a diagnosis of localised or locally advanced prostate cancer, and are scheduled to receive radiotherapy. Study details: Participants in this study will receive a supervised exercise intervention for the duration of their radiotherapy treatment (6-8 weeks). The exercise program involves aerobic and resistance exercises undertaken 3 times per week in an exercise clinic setting. The exercise sessions are 20-30 minutes in duration and take place immediately before radiotherapy treatment sessions. All participants will complete assessments at baseline (i.e. before starting radiotherapy) and after completion of their radiotherapy treatment in order to evaluate tumour oxygenation, treatment side effects, aerobic fitness and functional capacity, as well as health-related quality of life. Additionally, participants will undergo further assessments to evaluate tumour blood flow and immune cell mobilisation in response to single exercise sessions. It is hoped that exercise will be found to be feasible during radiotherapy treatment for prostate cancer patients and that this research will contribute important new information that will be useful to clinicians in the management of prostate cancer.